Literature DB >> 294954

Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

F Formelli, A M Casazza, A Di Marco, A Mariani, C Pollini.   

Abstract

The tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin was studied in comparison with that of their patient compounds, daunorubicin and doxorubicin, in mice bearing transplanted tumors. The doses administered were equal or equitoxic to those of their parent compounds. The levels of total fluorescence due to initial drugs and metabolites were determined on tissue extracts by fluorometry. After administration of equal doses of daunorubicin and 4-demethoxydaunorubicin, the calculated Cxt values of 4-demethoxydaunorubicin equivalents were higher than those for daunorubicin in all the organs tested except the heart. In animals treated with equitoxic doses, lower 4-demethoxydaunorubicin levels were found in all the organs tested. In mice treated with equitoxic doses of doxorubicin and 4-demethoxydoxorubicin, 4-demethoxydoxorubicin reached higher drug concentrations than doxorubicin in spleen and liver, whereas in all the other organs tested lower drug levels were found. The rate of drug disappearance from organs was slower in animals treated with 4-demethoxyderivatives than in those treated with their parent drugs.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 294954     DOI: 10.1007/bf00254742

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.

Authors:  R Supino; A Necco; T Dasdia; A M Casazza; A Di Marco
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

2.  A new antitumor antibiotic, carminomycin (NSC-180024).

Authors:  G F Gause; M G Brazhnikova; V A Shorin
Journal:  Cancer Chemother Rep       Date:  1974 Mar-Apr

3.  A fluorometric assay for daunomycin and adriamycin in animal tissues.

Authors:  H S Schwartz
Journal:  Biochem Med       Date:  1973-06

4.  Cytotoxic, antiviral, and antitumor activity of some derivatives of daunomycin (NSC-82151).

Authors:  A Di Marco; A M Casazza; T Dasdia; F Giuliani; L Lenaz; A Necco; C Soranzo
Journal:  Cancer Chemother Rep       Date:  1973 Sep-Oct

5.  Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats.

Authors:  J M Finkel; K T Knapp; L T Mulligan
Journal:  Cancer Chemother Rep       Date:  1969-06

6.  Daunorubicinol, a major metabolite of daunorubicin: isolation from human urine and enzymatic reactions.

Authors:  N R Bachur
Journal:  J Pharmacol Exp Ther       Date:  1971-06       Impact factor: 4.030

7.  Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts.

Authors:  C Peterson; A Trouet
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

8.  Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers.

Authors:  F Arcamone; L Bernardi; P Giardino; B Patelli; A Marco; A M Casazza; G Pratesi; P Reggiani
Journal:  Cancer Treat Rep       Date:  1976-07

9.  Experimental evaluation of anthracycline analogs.

Authors:  A M Casazza
Journal:  Cancer Treat Rep       Date:  1979-05

10.  Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.

Authors:  A Di Marco; A M Casazza; F Giuliani; G Pratesi; F Arcamone; L Bernardi; G Franchi; P Giardino; B Patelli; S Penco
Journal:  Cancer Treat Rep       Date:  1978-03
View more
  9 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 3.  Oral idarubicin--an anthracycline derivative with unique properties.

Authors:  M Goebel
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

Review 4.  Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.

Authors:  F Ganzina; M A Pacciarini; N Di Pietro
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.

Authors:  K Kolarić; V Potrebica; D Vukas; Z Mechl; B Sopkova
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Authors:  F Formelli; C Pollini; A M Casazza; A di Marco; A Mariani
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Phase I study of 4-demethoxydaunorubicin.

Authors:  V Bonfante; L Ferrari; F Villani; G Bonadonna
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Disposition and metabolism of [14-14C] 4-demethoxydaunorubicin HCl (idarubicin) and [14-14C]daunorubicin HCl in the rat. A comparative study.

Authors:  G Zini; G P Vicario; M Lazzati; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice.

Authors:  F Formelli; R Carsana; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.